Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Lexicon Pharmaceuticals Inc. currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. Prosecution is highly decentralized, with 4 distinct examiners and 4 distinct art units each handling a single matter. This one-to-one ratio between pending actions and examiners suggests that no single individual or unit currently dominates the company's patent pipeline.
HASTINGS, ALISON AZAR is listed as the busiest examiner, though they are responsible for only 1 pending office action. Because every examiner in the portfolio is currently handling exactly 1 pending action, the workload is perfectly distributed across the 4 distinct art units. This lack of concentration means that prosecution outcomes are subject to the varied perspectives of 4 different examiners rather than a centralized review process.
For the practitioner, this structure requires a strategy tailored to the specific habits of 4 different examiners. Since HASTINGS, ALISON AZAR and the other assigned examiners each handle only 1 pending office action, there is no opportunity to leverage a single examiner relationship for multiple outcomes. The 4 distinct art units also suggest that procedural experiences may vary across the different pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19053009 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | BRAUN, MADELINE E | — |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | CRAIGO, BAHAR ALAWI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | HASTINGS, ALISON AZAR | — |
| 19053009 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | BRAUN, MADELINE E | — |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1624 | 1 |
| 1629 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | HASTINGS, ALISON AZAR | 1627 | DP | Non-Final OA | — | Pending | Apr 28, 2025 |
| 19053009 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | BRAUN, MADELINE E | 1624 | §102§103Other | Non-Final OA | — | Pending | Feb 13, 2025 |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | CRAIGO, BAHAR ALAWI | 1699 | §101§102§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLexicon Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Alison Azar Hastings has the most, with 1 of Lexicon Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
